RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-42

I have seen a few comments on here this week claiming MSB's Remestemcel-L is dead in the water for COVID-19 ARDS and that SI should not be looking to undertake the additional phase 3 COVID-19 ARDS trial in the USA ..... 6,000 COVID-19 deaths in the last 3 days in the USA says otherwise IMO .... whatever FDA approved treatments were available to these people, sadly they didn't work



It will be interesting what the 12 month data shows from Mesoblasts ph3 COVID-19 ARDS trial shows as this data should be available in the next month or so :

https://clinicaltrials.gov/ct2/show/NCT04371393

MSCs in COVID-19 ARDS


Patients will be followed for 90 days post randomization, with assessment of pulmonary symptoms at 6 and 12 months.

Secondary Outcome Measures

7. Number of participants alive at 12 Months [ Time Frame: 12 Months ]

16. Length of stay [ Time Frame: 12 months ] Hospital length of stay

17. Readmissions [ Time Frame: 12 months ] number of readmission

18. Length of Stay in Intensive Care Unit [ Time Frame: 12 months ]

40. Pulmonary symptoms [ Time Frame: 12 months ] including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization



https://www.worldometers.info/coronavirus/#main_table